Premium
Phase I evaluation of ICRF‐187 (NSC‐169780) in patients with advanced malignancy
Author(s) -
Liesmann Jean,
Belt Robert,
Haas Charles,
Hoogstraten Barth
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810415)47:8<1959::aid-cncr2820470808>3.0.co;2-x
Subject(s) - medicine , leukopenia , toxicity , limiting , gastroenterology , bilirubin , phases of clinical research , pharmacology , mechanical engineering , engineering
ICRF‐187 (NSC‐169780), the (+) enantiomer of the racemic antineoplastic agent ICRF‐159 (NSC‐129943), was administered intravenously for five days every three weeks to 18 patients in a phase I study. Leukopenia was the dose‐limiting toxicity. Mild reversible elevations in SGOT and bilirubin were common. Other toxicities were mild and infrequent. Recommended doses of ICRF‐187 for phase II studies are 800 mg/m 2 for heavily pretreated patients and 1250 mg/m 2 for patients with little or no prior therapy. A daily five day intravenous schedule should be used. Other potential clinical uses of ICRF‐187 are discussed.